Eisai — Advancing Brain Health
历史时间线
- 1941: Eisai Co., Ltd. founded in Tokyo by Takejiro Ueno
- 1960s-70s: Expands into prescription pharmaceuticals
- 1990s: Establishes US subsidiary, begins global expansion
- 2010: Aricept (donepezil) becomes one of the best-selling Alzheimer's drugs ever
- 2019: Lecanemab (Leqembi) receives FDA breakthrough therapy designation for Alzheimer's
- 2023: Leqembi receives full FDA approval — landmark in Alzheimer's treatment
- 2024: Expanding neuroscience pipeline with new molecular entities
商业模式
- Neurology: Alzheimer's, epilepsy, migraine — core therapeutic area
- Oncology: Multiple cancer drug candidates in development
- Vitality: GI and other therapeutic areas
- Global partnerships: Co-development with Biogen (Leqembi)
护城河分析
- Alzheimer's leadership: Leqembi positions Eisai at the forefront of Alzheimer's treatment
- R&D focus: 20%+ of revenue invested in R&D — above industry average
- hPHC philosophy: "human health care" philosophy drives patient-centric drug development
- Strategic partnerships: Biogen collaboration shares risk and accelerates development
关键数据
- Revenue: ¥800B+ (~$5.5B) annually
- Leqembi potential: Blockbuster status expected with $5B+ peak sales estimate
- R&D spend: ¥160B+ annually
- Employees: 11,000+ across 30+ countries
有趣事实
- Eisai's name comes from "Eisai" (衛佐), the founder's belief that medicine should "aid and protect" (衛る 佐ける) people's health — the company motto is "ihl" (integrative innovation for health and life)
- The Aricept-Lecanemab journey spans 30+ years of Alzheimer's research at Eisai, making it one of the longest and most committed pharma efforts in the disease